<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>Biological Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/81141413-9AE6-4662-BD73-F91C42871C65"><gtr:id>81141413-9AE6-4662-BD73-F91C42871C65</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Lloyd</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC3E968D-06C2-4F03-9987-D58301F99BC6"><gtr:id>DC3E968D-06C2-4F03-9987-D58301F99BC6</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Gerrard</gtr:otherNames><gtr:surname>Dowson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1FD4D789-FFE2-40DF-91BF-73143F6A553A"><gtr:id>1FD4D789-FFE2-40DF-91BF-73143F6A553A</gtr:id><gtr:firstName>David Ian</gtr:firstName><gtr:surname>Roper</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DDBB3F10-D3B5-4C13-BD8E-415EF8EBE9C9"><gtr:id>DDBB3F10-D3B5-4C13-BD8E-415EF8EBE9C9</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>David Howard</gtr:otherNames><gtr:surname>Bugg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500643"><gtr:id>24143DEE-9B33-4C02-823B-46F46EC46784</gtr:id><gtr:title>UK-BaCWAN: UK-Bacterial Cell Wall Assembly Network</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500643</gtr:grantReference><gtr:abstractText>Millions of people die each year from bacterial infections and tens of millions suffer from the consequences of these infections. The discovery of the antibiotic penicillin once opened the door to treat these infections by stopping bacteria making the polymer in the cell wall that holds them together. This polymer, called peptidoglycan, is made up of an interlocking network of sugars and strings of amino acids (peptides). Specialised proteins (called PBPs), with the ability to stitch together these sugars and peptides are the targets inhibited by penicillin, stopping cell wall synthesis and killing the bacterium. Many important bacteria are now no longer killed by penicillin and other antibiotics that attack other stages in the production of peptidoglycan. Bacteria have changed, evading the action of these antibiotics. We need to fight back, by using the advanced computing power at our disposal to design new classes of antibiotics, compounds that will work against multiply resistant bacteria like MRSA, and help combat the harmful effects of our immune system when it over responds to infection. 

The group at Warwick has brought together a UK-wide team from microbiology, biochemistry, chemistry, structural biology, physiology, engineering and mathematics to crack this problem. They will have, for the first time, the combined tools and new chemical reagents (to be made for the team at a cost efficient central location at Warwick) to look in minute detail how peptidoglycan is made, how we could stop this process by the development of new inhibitors (antibiotics) and how fragments of peptidoglycan interact with our bodies during the process of infection. This capacity for discovery, being lost elsewhere, will provide a unique forum for the development of new compounds.</gtr:abstractText><gtr:technicalSummary>Bacterial cell wall assembly is an important target for the development of novel antibacterial agents, and is intimately connected with the emergence of antibiotic resistance around the world. There are significant research programmes carried out in UK laboratories in this area, but at present these activities are somewhat fragmented, with groups in Chemistry, Biochemistry, and Microbiology departments following different areas related to this problem. Therefore we propose to establish a UK Network in bacterial cell wall assembly, which can bring together expertise different disciplines and provide a forum for the additional involvement of industrial and physical scientists, to inform the network of industrial interests and emerging physical techniques. The principal vehicle for this network will be a series of bi-yearly meetings involving chemists, biochemists, microbiologists, computational, industrial and physical scientists to stimulate new inter-disciplinary research and collaboration in this area. The establishment of a web site to distribute information to members, other scientists and the general public will also augment these meetings. We also wish to facilitate new collaborative research programmes that will arise from this network by funding inter-laboratory and interdisciplinary visits for students, postdoctoral researchers and PIs, enabling technology and technique transfer to stimulate future research efforts within the UK scientific community.</gtr:technicalSummary><gtr:fund><gtr:end>2008-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>164933</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5571A9EE-1F03-479E-B5A9-301121CF10BB</gtr:id><gtr:impact>Web cast detailing research activity of the interdisciplinary group at Warwick supported by MRC fundinghttp://www2.warwick.ac.uk/newsandevents/pressreleases/research_could_put. Subsequent press release was reported all over the world

Invitation to scientific meetings and policy making events.</gtr:impact><gtr:outcomeId>F4DA3EECA27</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Getting to grips with antibiotic resistance</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B7A361F9-E49A-414E-9C69-0D7B6BA466F3</gtr:id><gtr:impact>The School of Life Sciences at Warwick hosted members of the public and press for a presentational evening with talks, lab tours and demonstrations in an event entitled: &amp;quot;Getting to grips with antibiotic resistance&amp;quot; This event was held in antibiotic awareness week in November 2016 and hosted around 90 visitor</gtr:impact><gtr:outcomeId>58c02c947f9c47.00975096</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www2.warwick.ac.uk/fac/sci/lifesci/outreach/next/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CIHR-MRC Network Funding</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2A88031B-F833-4E97-A209-CCA5A6521247</gtr:id><gtr:outcomeId>C95CBE96AEF0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>229138</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AWM-Science City, Translational Medicine</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Advantage West Midlands</gtr:fundingOrg><gtr:id>2792764E-0574-43DE-8EA2-C67B1B239301</gtr:id><gtr:outcomeId>08D2F43E9E10</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>731794</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project grant</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>15BD2E82-DE50-4405-9CB6-38D097BBA3D5</gtr:id><gtr:outcomeId>DfWPyAtUrPJ0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>410114</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>0275AA70-8D3A-476F-AC35-43146A4A49DB</gtr:id><gtr:outcomeId>bxdtJDpumfq0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1261509</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>teamCanUK: Novel antibacterial targets, assays, probes and oportunities in bacterial cell wall biogenesis</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1E3314CB-7A2A-4C8C-A9CE-B4ED674AD6DD</gtr:id><gtr:outcomeId>daKFR1BvPZr0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>website: www.warwick.ac.uk/go/bacwan</gtr:description><gtr:id>B7BA2F42-D304-4DBE-AE99-18F754221AD8</gtr:id><gtr:impact>The research materials provided by the BACWAN synthetic facility provide much needed and high value intermediates required for bacterial cell wall research.</gtr:impact><gtr:outcomeId>E4EA7635815</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>BACWAN Website and peptidoglycan synthesis facility</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www2.warwick.ac.uk/fac/sci/lifesci/people/droper/bacwan/</gtr:url><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C39BE868-4234-468A-8FDE-EE68DAB2AC5F</gtr:id><gtr:title>Pseudomonas aeruginosa MurE amide ligase: enzyme kinetics and peptide inhibitor.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8c2efad2f3086b8203550051fe5ee4d"><gtr:id>b8c2efad2f3086b8203550051fe5ee4d</gtr:id><gtr:otherNames>Paradis-Bleau C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>FHaYCtVB2n3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ACB3972-A516-4FB1-A680-7E84C216F1FE</gtr:id><gtr:title>IFN-gamma enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/341f79d80e200de30d4ceb0318cb1117"><gtr:id>341f79d80e200de30d4ceb0318cb1117</gtr:id><gtr:otherNames>T?temeyer S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>18CF82EDEED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>251DED87-A745-443D-ABD6-A126C513D3E3</gtr:id><gtr:title>Full-length structure of the major autolysin LytA.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99f6924f8765fc02490873fd4b290945"><gtr:id>99f6924f8765fc02490873fd4b290945</gtr:id><gtr:otherNames>Li Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>56d722bb729420.66330094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>317A768B-CA91-43E8-8D23-C15034315A73</gtr:id><gtr:title>Inhibition of tRNA-dependent ligase MurM from Streptococcus pneumoniae by phosphonate and sulfonamide inhibitors.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fc69d5be4c1fa2234e04140b7de0313"><gtr:id>6fc69d5be4c1fa2234e04140b7de0313</gtr:id><gtr:otherNames>Cressina E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>B662087D306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA63443C-4EF0-4ADD-A9BC-75E48DBA4B0C</gtr:id><gtr:title>Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7afc5d17144907949d5694a64160a7b9"><gtr:id>7afc5d17144907949d5694a64160a7b9</gtr:id><gtr:otherNames>Zuegg J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56d722bb1f9128.27540515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7442960-224F-455F-B4F6-5A9B69444E61</gtr:id><gtr:title>Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e93a23805972b417db19d67fd4fe977"><gtr:id>4e93a23805972b417db19d67fd4fe977</gtr:id><gtr:otherNames>Tran AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c02a64c61720.20099677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A8D3955-F0AE-4E2A-9422-5C3CF0E696F9</gtr:id><gtr:title>Expression, purification, crystallization and preliminary characterization of uridine 5'-diphospho-N-acetylmuramoyl L-alanyl-D-glutamate:lysine ligase (MurE) from Streptococcus pneumoniae 110K/70.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04b8f3e1f8961e5fe51fc8ea61212f8e"><gtr:id>04b8f3e1f8961e5fe51fc8ea61212f8e</gtr:id><gtr:otherNames>Blewett AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>55E3490FA02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C57DD723-AD07-432D-A0BA-B624504ABF46</gtr:id><gtr:title>Prospects for novel inhibitors of peptidoglycan transglycosylases.</gtr:title><gtr:parentPublicationTitle>Bioorganic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a332b4e13c1c61778aea16402016602b"><gtr:id>a332b4e13c1c61778aea16402016602b</gtr:id><gtr:otherNames>Galley NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0045-2068</gtr:issn><gtr:outcomeId>546217c0dff132.91602592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F3A9695-E18E-47C9-A897-772A61257971</gtr:id><gtr:title>Substitutions in PBP2b from ?-Lactam-resistantHave Different Effects on Enzymatic Activity and Drug Reactivity.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f61cc3376b1e41b222561466e62e8d5e"><gtr:id>f61cc3376b1e41b222561466e62e8d5e</gtr:id><gtr:otherNames>Calvez P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>58c02a6506ce80.31659681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>131FAAB6-BB3E-415C-A444-88A1F80E01A4</gtr:id><gtr:title>A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e8057960405977683868ea29ef09be7"><gtr:id>5e8057960405977683868ea29ef09be7</gtr:id><gtr:otherNames>Besong GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>FB2A57C0380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F302137-68B6-4513-9560-FA1AC684E6EF</gtr:id><gtr:title>Bacterial cell division: experimental and theoretical approaches to the divisome.</gtr:title><gtr:parentPublicationTitle>Science progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e345351174863be97af96128f822b7e"><gtr:id>7e345351174863be97af96128f822b7e</gtr:id><gtr:otherNames>Broughton CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0036-8504</gtr:issn><gtr:outcomeId>56d722bb9fa0a5.88245626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1560E387-DE6D-4157-B025-63F9EEE9F460</gtr:id><gtr:title>Structure of the diaminopimelate epimerase DapF from Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/286e637dccc3e05c93cc3ebe3583bb1c"><gtr:id>286e637dccc3e05c93cc3ebe3583bb1c</gtr:id><gtr:otherNames>Usha V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>D1C22F7C1A5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C0CC359-78FB-44AA-955F-876C03ADBFBF</gtr:id><gtr:title>Characterization of tRNA-dependent peptide bond formation by MurM in the synthesis of Streptococcus pneumoniae peptidoglycan.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d9a44e5e7a61959fd7e4276275fb157"><gtr:id>7d9a44e5e7a61959fd7e4276275fb157</gtr:id><gtr:otherNames>Lloyd AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>090E328A6EB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7236A16C-1D4E-44BF-AFD4-3D3DD71A8D6F</gtr:id><gtr:title>Fluorescent reagents for in vitro studies of lipid-linked steps of bacterial peptidoglycan biosynthesis: derivatives of UDPMurNAc-pentapeptide containing d-cysteine at position 4 or 5.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee62c7d4e797a1b215c3e09aba0b983d"><gtr:id>ee62c7d4e797a1b215c3e09aba0b983d</gtr:id><gtr:otherNames>Schouten JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>CDE44BFE8DD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA0CFF9D-C4EE-4533-BAD5-B8771951A76E</gtr:id><gtr:title>Nod1 signaling overcomes resistance of S. pneumoniae to opsonophagocytic killing.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cff11cd2c359666d4f4782b083b20fb1"><gtr:id>cff11cd2c359666d4f4782b083b20fb1</gtr:id><gtr:otherNames>Lysenko ES</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>440B99D466E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1DFDCAB-9ECB-4A81-8AA3-A1C4689FE1E3</gtr:id><gtr:title>Reconstruction of diaminopimelic acid biosynthesis allows characterisation of Mycobacterium tuberculosis N-succinyl-L,L-diaminopimelic acid desuccinylase.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/286e637dccc3e05c93cc3ebe3583bb1c"><gtr:id>286e637dccc3e05c93cc3ebe3583bb1c</gtr:id><gtr:otherNames>Usha V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c02a65723ff4.09451289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D480E2D1-2A8C-43F8-B171-07743B978066</gtr:id><gtr:title>Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/570dcdda9f8064c09def9cbe6583ab32"><gtr:id>570dcdda9f8064c09def9cbe6583ab32</gtr:id><gtr:otherNames>Vajs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>58c02a653d3de0.78962735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3B8BAED-DDDE-44E2-99DB-1B2884017158</gtr:id><gtr:title>Crystal structure of penicillin binding protein 4 (dacB) from Escherichia coli, both in the native form and covalently linked to various antibiotics.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1da6a367fe4a465c03e0888c484b112b"><gtr:id>1da6a367fe4a465c03e0888c484b112b</gtr:id><gtr:otherNames>Kishida H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>2E46671100D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEEBFAC7-6C86-45CD-820C-FA452D0C6D0A</gtr:id><gtr:title>Mutational analysis of the substrate specificity of Escherichia coli penicillin binding protein 4.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32918b04931fabb0631d6ae72adc8bf8"><gtr:id>32918b04931fabb0631d6ae72adc8bf8</gtr:id><gtr:otherNames>Clarke TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>pm_15655_15_19209901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DA2F561-843E-468A-BAF3-9028B621D2CF</gtr:id><gtr:title>Design and synthesis of new hydroxyethylamines as inhibitors of D-alanyl-D-lactate ligase (VanA) and D-alanyl-D-alanine ligase (DdlB).</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcc76e1e0552de72eb6ee20f503787e3"><gtr:id>bcc76e1e0552de72eb6ee20f503787e3</gtr:id><gtr:otherNames>Sova M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>F2P2ByWo7GB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E389C119-ADB6-41BE-AF60-8CA0F6B12879</gtr:id><gtr:title>Crystallization and preliminary X-ray analysis of a D-alanyl-D-alanine ligase (EcDdlB) from Escherichia coli.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section F, Structural biology and crystallization communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76dd1cc6514f661051e712975c590a1f"><gtr:id>76dd1cc6514f661051e712975c590a1f</gtr:id><gtr:otherNames>Batson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1744-3091</gtr:issn><gtr:outcomeId>kskP2U7vf1C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21E24BD1-B609-4709-8012-096C35894609</gtr:id><gtr:title>Core Steps of Membrane-Bound Peptidoglycan Biosynthesis: Recent Advances, Insight and Opportunities.</gtr:title><gtr:parentPublicationTitle>Antibiotics (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f98baa5319d785b8b6676b8f91f56aa"><gtr:id>6f98baa5319d785b8b6676b8f91f56aa</gtr:id><gtr:otherNames>Teo AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2079-6382</gtr:issn><gtr:outcomeId>56d723e6b86149.14631704</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500643</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>